

L Number	Hits	Search Text	DB	Time stamp
1	773	tetrahydropyrimidin or tetrahydropyrimidinyl	USPAT; US-PGPUB	2003/07/22 15:43
2	552	(tetrahydropyrimidin or tetrahydropyrimidinyl) and (naphthalene or naphthyl)	USPAT; US-PGPUB	2003/07/22 15:44
3	75	((tetrahydropyrimidin or tetrahydropyrimidinyl) and (naphthalene or naphthyl)) and ((sulfonyl adj amino) or sulfonamide or sulfonamido)	USPAT; US-PGPUB	2003/07/22 15:45

EAST
10/831, 121

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

10/ 031,121

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:03:20 ON 22 JUL 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:03:41 ON 22 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

DICTIONARY FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10031121.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

FULL SEARCH INITIATED 10:04:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 109 TO ITERATE

0 ANSWERS


```
=> s 'naphthalene-1-sulfonylamino' and '1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl'
```

L3 4 'NAPHTHALENE-1-SULFONYLAMINO' AND '1,4,5,6-TETRAHYDROPYRIMIDIN-2-
-YLCARBAMOYL'

'1-' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

IN 9H-Purine-9-propanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-6-[4-
[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-,
1,1-dimethylethyl ester, (.alpha.S)- (9CI)

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
 SAM - Index Name, MF, and structure - no RN
 FIDE - All substance data, except sequence data
 IDE - FIDE, but only 50 names
 SQIDE - IDE, plus sequence data
 SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
 SQD - Protein sequence data, includes RN
 SQD3 - Same as SQD, but 3-letter amino acid codes are used
 SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
 EPROP - Table of experimental properties
 PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
 APPS -- Application and Priority Information
 BIB -- CA Accession Number, plus Bibliographic Data
 CAN -- CA Accession Number
 CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
 IND -- Index Data
 IPC -- International Patent Classification
 PATS -- PI, SO
 STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
 IBIB -- BIB, indented, with text labels
 ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
 HELP FORMATS -- To see detailed descriptions of the predefined formats..
 HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

10/ 031,121

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

180.49

180.70

FILE 'CAPLUS' ENTERED AT 10:08:21 ON 22 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2003 VOL 139 ISS 4

FILE LAST UPDATED: 21 Jul 2003 (20030721/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:03:20 ON 22 JUL 2003)

FILE 'REGISTRY' ENTERED AT 10:03:41 ON 22 JUL 2003

L1 STRUCTURE UPLOADED

L2 0 S L1 FUL

L3 4 S 'NAPHTHALENE-1-SULFONYLAMINO' AND '1,4,5,6-TETRAHYDROPYRIMIDI

FILE 'CAPLUS' ENTERED AT 10:08:21 ON 22 JUL 2003

=> s l3

L4 2 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:450930 CAPLUS

DOCUMENT NUMBER: 135:46196

TITLE: Preparation of (tetrahydropyrimidinylcarbamoylethyl)thienylalanine derivatives as inhibitors of cell adhesion

INVENTOR(S): Gadek, Thomas; Gourvest, Jean-Francois; Peyman, Anuschirwan; Ruxer, Jean-Marie; Scheunemann, Karl-Heinz

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

 EP 1108721 A1 20010620 EP 1999-124971 19991215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 WO 2001044237 A1 20010621 WO 2000-EP12877 20001212
 W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ,
 EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT,
 LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US,
 UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1240161 A1 20020918 EP 2000-989987 20001212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2003105080 A1 20030605 US 2002-169612 20020923
 PRIORITY APPLN. INFO.: EP 1999-124971 A 19991215
 WO 2000-EP12877 W 20001212
 OTHER SOURCE(S): MARPAT 135:46196
 GI



AB Title compds. (I) [wherein A and B = independently H, alkyl, cycloalkyl(alkyl), aryl(alkyl), halo, CN, CF₃, NO₂, CO₂H, alkoxy(alkyl), alkoxyalkyl, (aryl)alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxyalkoxy, alkylaminocarbonyl, (di)alkylamino, alkylsulfonyl, or aminosulfonyl; or A and B together with the thiophene ring to which they are attached may form a fused ring system; X = alkanediyl, alkenendiyl, or alkynediyl, where 1 C may be replaced by N, O, or S, etc.; Y = a bond, SO₂, CO, CO₂, SO₂NR₃', or CONR₃'; R₁ = (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl); R₂ = COR₄, CSR₄, SO₂R₄, POR₄R₄', or a heterocycle; R₃ and R₃' = independently H, alkyl, cycloalkyl(alkyl), or aryl(alkyl); R₄ and R₄' = independently OH, (aryl)alkoxy, (aryl)alkylcarbonyloxyalkoxy, or NR₅NR₅'; R₅ and R₅' = independently H, alkyl, cycloalkyl(alkyl), or aryl(alkyl); or R₅ and R₅' together with the N to which they are attached may form a heterocycle] were prepd. as vitronectin receptor (VnR) antagonists. For example, coupling 5-[5-((2S)-2-amino-2-tert-butoxycarbonyl ethyl)thiophen-2-yl]pentanoic acid (6-step prepn. given) and naphthalene-1-sulfonyl chloride to give the sulfonamide, followed by amidation with 1,4,5,6-tetrahydropyrimidin-2-ylamine and hydrolysis using TFA, gave (S)-II. II inhibited the binding of kistrin to human VnR .alpha.v.beta.3 and the binding of human embryonic kidney 293 cells to human vitronectin with IC₅₀ values of 0.023 .mu.M and

10/ 031,121

0.42 .mu.M, resp. As cell adhesion inhibitors, I are suitable for the therapy and prophylaxis of illnesses which are based on or influenced by the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes, e.g. osteoporosis, angiogenesis, and proliferation of cells of the vascular smooth musculature (no data).

IT 344619-98-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of (tetrahydropyrimidinylcarbamoylalkyl)thienylalanine derivs. as vitronectin receptor antagonists for use as cell adhesion inhibitors)

RN 344619-98-3 CAPLUS

CN 2-Thiophenepropanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-5-[5-oxo-5-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]pentyl]-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 344619-90-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (tetrahydropyrimidinylcarbamoylalkyl)thienylalanine derivs. as vitronectin receptor antagonists for use as cell adhesion inhibitors)

RN 344619-90-5 CAPLUS

CN 2-Thiophenepropanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-5-[5-oxo-5-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]pentyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:10663 CAPLUS

10/ 031,121

DOCUMENT NUMBER: 134:71601
 TITLE: Substituted purine derivatives, method of preparation and use as inhibitors of cell adhesion
 INVENTOR(S): Knolle, Jochen; Peyman, Anuschirwan; Gourvest, Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.
 SOURCE: Eur. Pat. Appl., 41 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065208	A1	20010103	EP 1999-112637	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001002399	A1	20010111	WO 2000-EP5921	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1196416	A1	20020417	EP 2000-940406	20000626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000012050	A	20021231	BR 2000-12050	20000626
JP 2003503497	T2	20030128	JP 2001-507836	20000626
EE 200100713	A	20030415	EE 2001-713	20000626
BG 106229	A	20020830	BG 2001-106229	20011217
NO 2001006403	A	20020301	NO 2001-6403	20011228
PRIORITY APPLN. INFO.:			EP 1999-112637	A 19990702
			WO 2000-EP5921	W 20000626
OTHER SOURCE(S):		MARPAT 134:71601		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to purine derivs. I. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl-(C1-C8)alkyl, F, Cl, Br, OH, CN, CF₃, NO₂, CO₂H, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonfylamino, (C5-C14)arylsulfonfylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonfyl, aminosulfonfyl, (C5-C14)arylsulfonfyl, (C5-C14)aryl-(C1-C8)alkylsulfonfyl, (C5-C14)aryl or (C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different, or B denotes an arom. or nonarom. ring system that is fused to the 6-membered ring contg. the groups G and Z. D is -C(O)-N(R₆)-, -NR₆-C(O)-, -NR₆-C(O)-N(R₆)-, -NR₆-C(S)-N(R₆)-, -C(S)-N(R₆)- or -C(R₆):N-N(R₆)-, where the divalent residues representing D are bonded to the group E via the free bond on their right side. E is a residue from the series consisting of possibly substituted 2-pyrimidinyl, pyrrolyl, 2-imidazolyl, 2-imidazolin-2-yl, 2-pyridinyl many other N

heterocycles, R6-C(:NR6)-NR6-, and R6R6'N-C(:NR6)-. G is N, CH or C((C1-C4)alkyl). X is H, -NR6R6', F, Cl, Br, -OR6, -SR6, hydroxy-(C1-C6)alkyl-NH-, (hydroxy-(C1-C6)alkyl)2N-, amino-(C1-C6)alkyl-NH-, (amino-(C1-C6)alkyl)2N-, hydroxy-(C1-C6)alkyl-O-, hydroxy-(C1-C6)alkyl-S- or -NH-C(O)-R6. Y has one of the meanings of R6 or is F, Cl, Br, CN, -NR6R6', -OR6, -SR6 or hydroxy-(C1-C6)alkyl-NH-. Z is N or CH. R1 is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl-(C1-C8)alkyl, where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of F, Cl, Br, CN, CF3, NO2, CO2H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C8)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl-(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl-(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl. R2 is -C(O)R5, -C(S)R5, -S(O)PR5, -P(O)R5R5' or a residue of a 4-membered to 8-membered satd. or unsatd. heterocycle which contains 1-4 heteroatoms from the series consisting of N, O and S. R5 and R5' are OH, (C1-C8)alkoxy, (C5-C14)aryl-(C1-C8)alkoxy, (C1-C8)alkylcarbonyloxy-(C1-C4)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyloxy-(C1-C8)alkoxy- or -NR6R6', where the residues R5' and R5' are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl where in the aryl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or (C5-C14)aryl-(C1-C8)alkyl, where in the aryl moiety of the arylalkyl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or R6 and R6' together with the N atom to which they are bonded form a 4-8-membered ring system which in addn. to the N atom to which R6 and R6' are bonded can contain 1-3 ring heteroatoms N, O and S and which can be unsatd. or satd., where all residues R6 and R6' are independent of one another and can be identical or different. R = 0-4; s = 0-4; v = 1-3; p = 1-2. The present invention also relates to stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown in I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the prepn. of I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compns. comprising them. The process for the prepn. comprises reacting II (L1 = leaving group; R15 = R1SO2 or an amino protecting group) with III or IV; B, D, E, G, X, R2 and s are as defined above but functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzoyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester was reacted with piperidine-4-carboxylic acid in the presence of N,O-bis(trimethylsilyl)acetamide to give 1-(9-((2S)-2-benzoyloxycarbonylamino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid, which was reacted with 2-amino-1,4,5,6-tetrahydropyrimidine hydrochloride to give (2S)-2-Benzoyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester, which was deprotected at N, N-sulfonated

10/ 031,121

by various sulfonyl chlorides and hydrolyzed to give products such as (2S)-2-(naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid.

IT 315212-33-0P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; substituted purine derivs., method of prepn. and use as inhibitors of cell adhesion)

RN 315212-33-0 CAPLUS

CN 9H-Purine-9-propanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 315212-18-1P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted purine derivs., method of prepn. and use as inhibitors of cell adhesion)

RN 315212-18-1 CAPLUS

CN 9H-Purine-9-propanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 031,121



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:03:20 ON 22 JUL 2003)

FILE 'REGISTRY' ENTERED AT 10:03:41 ON 22 JUL 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 FUL
L3 4 S 'NAPHTHALENE-1-SULFONYLAMINO' AND '1,4,5,6-TETRAHYDROPYRIMIDI

FILE 'CAPLUS' ENTERED AT 10:08:21 ON 22 JUL 2003

L4 2 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.49	190.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 10:08:54 ON 22 JUL 2003